FDA Completeness Assessment Correspondence

The FDA has published a notice regarding Completeness Assessment Correspondence, authored by CDER, and dated March 25, 2026. The document itself is not available for viewing or download on Regs.gov, with only metadata and a link to further information provided. This correspondence likely relates to the FDA's review process for drug applications, specifically concerning the completeness of submissions.

While no specific actions are mandated by this notice, drug manufacturers and pharmaceutical companies should be aware that this type of correspondence is part of the regulatory review process. Compliance officers should note the date of this posting and be prepared to address any inquiries or requirements stemming from such assessments if their organization is involved in drug applications with the FDA.